What Is the Difference Between IGF-1 LR3 and Native IGF-1?

In the body, native IGF-1 is tightly regulated: more than 90% of circulating IGF-1 is bound at any given time to a family of IGF-binding proteins (IGFBPs), which control how much free hormone is available to interact with the IGF-1 receptor. This tight regulation is part of normal physiology but makes native IGF-1 a difficult tool for laboratory researchers who want to study sustained receptor activation over an extended experimental window.

IGF-1 LR3's structural modification — the added N-terminal sequence and Arg3 substitution — reduces its affinity for IGFBPs substantially compared to native IGF-1, based on published in-vitro binding studies. That reduced binding is the entire rationale for the analog's existence: it is not a more "potent" version of IGF-1 at the receptor level so much as a version that stays free and active in solution for longer, which researchers use to study prolonged IGF-1 receptor signaling.

Both native IGF-1 and IGF-1 LR3 sit entirely outside REVIVE LAB UAE's catalog. This comparison is published as general research information only, describes no dosing or administration, and does not represent an offer to sell either compound.